Brokers Set Expectations for MAZE Q2 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Maze Therapeutics in a research report issued on Wednesday, July 23rd. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings per share of ($1.15) for the quarter. HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. HC Wainwright also issued estimates for Maze Therapeutics' Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.41) EPS, FY2026 earnings at ($3.76) EPS, FY2027 earnings at ($4.07) EPS, FY2028 earnings at ($1.92) EPS and FY2029 earnings at ($1.59) EPS.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

MAZE has been the subject of a number of other research reports. Guggenheim reiterated a "buy" rating and issued a $19.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Wedbush started coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective for the company. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Maze Therapeutics currently has an average rating of "Buy" and a consensus target price of $25.60.

Maze Therapeutics Stock Performance

Shares of MAZE traded up $0.37 during trading hours on Friday, reaching $16.82. 51,167 shares of the company traded hands, compared to its average volume of 141,521. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $19.19. The firm has a fifty day moving average of $13.07.

Institutional Trading of Maze Therapeutics

Several large investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund acquired a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $25,000. CWM LLC bought a new position in Maze Therapeutics in the 2nd quarter valued at $28,000. Corebridge Financial Inc. acquired a new position in Maze Therapeutics in the first quarter worth $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Maze Therapeutics during the first quarter worth $57,000. Finally, Rhumbline Advisers acquired a new stake in shares of Maze Therapeutics in the first quarter valued at $80,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.